Nimotuzumab Combined With Chemoradiotherapy Versus Chemoradiotherapy for Local Advanced Cervical Squamous Cell Carcinoma

Inclusion Criteria: 1. Aged 18-75 years old; 2. Histologically diagnosed primary cervical squamous cell carcinoma, with clinical stage IB3-IVA (FIGO 2018); 3. At least one measurable lesion according to RECIST 1.1; 4. Absence of severe hematopoietic dysfunction and heart, lung, liver, kidney dysfunction and immunodeficiency, laboratory test results meet the following criteria: Hemoglobin ≥ 90 g/L; Absolute neutrophil count ≥ 2 × 109/L or white blood cell count ≥ 4.0 × 109/L; Platelet count ≥ 100 × 109/L; Aspartate aminotransferase (AST) ≤ 2.5 × ULN Alanine aminotransferase (ALT) ≤ 2.5 × ULN Total bilirubin ≤ 1.5 × ULN; Serum creatinine ≤ 1.0 × ULN; 5. ECOG score 0-2 points; 6. Expected survival ≥ 3 months; 7. Women of childbearing potential must have a negative serum or urine HCG within 72 hours prior to enrollment (postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential. A pregnancy test is not required for women who have demonstrated tubal ligation); 8. No intrauterine device; 9. Women of childbearing potential who are willing to take medically recognized contraceptive measures during the trial; 10. Compliance is good and informed consent is voluntarily signed. Exclusion Criteria: 1. Cervical adenocarcinoma and rare pathological types of malignant tumors; 2. Previous surgery for cervical cancer, pelvic radiation therapy, systemic chemotherapy, tumor targeted therapy, immunotherapy; 3. Ureteral obstruction, inability to place ureteral stent or pyelostomy; 4. Pregnant or lactating women; 5. Patients with rectovaginal fistula/vaginovesical fistula/uncontrolled vaginal bleeding or at risk of fistula; 6. Human immunodeficiency virus (HIV) infection; 7. Active hepatitis B (the quantitative detection result of HBV DNA exceeds the lower limit of detection), or HCV infection (the quantitative detection result of HCV RNA exceeds the lower limit of detection); 8. Patients have a serious underlying condition that precludes safe administration of trial treatment. Including but not limited to active infection requiring systemic drug therapy: decompensated heart failure (NYHA Class III and IV), unstable angina pectoris, acute myocardial infarction within 3 months prior to enrollment; 9. Patients with a history of other malignant tumors (except cured cutaneous basal cell carcinoma); 10. Patients with Crohn's disease and ulcerative colitis; 11. Patients who are participating in other clinical trials or have stopped clinical trials for less than 4 weeks; 12. Patients with known hypersensitivity to Nimotuzumab or its components; 13. Patients with contraindications to cisplatin; 14. Patients with neurological or psychiatric disorders affecting cognitive ability; 15. Patients whose lesions cannot be treated with intracavitary radiotherapy as assessed by the investigator; 16. Other reasons that, in the judgment of the investigator, would make the patient inappropriate for the study.